Stay Connected

Let us support you on your journey and connect you to the TAKHZYRO community. We’ll bring you TAKHZYRO news and helpful information about living with HAE. Fill in the form below to start.

How would you like to receive information?* (select all that apply)

Text messages (6 short texts with links to help you learn more about TAKHZYRO)

Direct mail (please fill out address below)

Email Address*

Cell Phone Number*

Which best describes you or your loved one?*

I have not been diagnosed with HAE I have been diagnosed with HAE I have a loved one with HAE

What best describes your current HAE treatment plan? (Optional)

On-demand only Both on-demand and preventive I’m not currently treating

Address 1

Address 2

City

ZIP Code

State

Yes, I am interested in receiving information from Takeda via the contact information provided above.*

By clicking “Submit” I certify that I am 18 years of age or older.

By providing your information, you consent to receiving marketing and promotional communications and other information from Takeda. You hereby give consent to Takeda, its affiliates, and their agents and representatives to send communications and information to you via the contact information you have provided above. This consent will be in effect until such time as you opt out of communications from Takeda. If, at any time, you no longer wish to receive communications from Takeda, you can opt out by calling 1-877-TAKEDA-7 (1-877-825-3327). Please see our privacy policy.

Mobile Terms & Conditions

By agreeing to these TAKHZYRO Text Message Terms and Conditions, you agree to receive text messages on your mobile device subject to the Terms & Conditions described below. You understand that this consent is not a condition of purchase or use of TAKHZYRO or of any Takeda product or service. Collapse Expand to read more.

Depending on program enrollment, participants will receive an average of
- 2-5 text messages each month while enrolled in the Text Reminder Program (“Reminder Program”), or
- 1-5 text messages each month while enrolled in the Informational Program (“Informational Program”)
There is no fee payable to Takeda to receive text messages; however, your carrier's message and data rates may apply
Data obtained from you in connection with your registration for, and use of, this SMS service may include your phone number and/or email address, related carrier information.
- For the Reminder Program, elements of dosing timing will be used to administer the Reminder Program and to provide benefits such as dosing reminders and updates and alerts. Visit our Privacy Policy. You may also receive additional educational and promotional information about the product.
Takeda will not be liable for any delays in the receipt of any SMS messages as delivery is subject to effective transmission from your network operator
This Program is valid with most major U.S. carriers, including: Verizon Wireless, Sprint, Nextel, Boost, T-Mobile®, AT&T, Alltel, ACS Wireless, Bluegrass Cellular, Carolina West Wireless, CellCom, Cellular One of East Central Illinois (ECIT), Cincinnati Bell, Cricket, C Spire Wireless, Duet IP (AKA Max/Benton/Albany), Element Mobile, Epic Touch, GCI Communications, Golden State, Hawkeye (Chat Mobility), Hawkeye (NW Missouri Cellular), Illinois Valley Cellular (IVC), Inland Cellular, iWireless, Keystone Wireless (Immix/PC Management), Metro, MobiPCS, Mosaic, MTPCS/Cellular One (Cellone Nation), Nex-Tech Wireless, Panhandle Telecommunication, Pioneer, Plateau, Revol Wireless, Rina-Custer, Rina-All West, Rina-Cambridge Telecom Coop, Rina-Eagle Valley Comm, Rina-Farmers Mutual Telephone Co, Rina-Nucla Nutria Telephone Co, Rina-Silver Star, Rina-South Central Comm, Rina-Syringa, Rina-UBET, Rina-Manti, Simmetry, South Canaan/Cellular One of NEPA, Thumb Cellular, Union Wireless, United Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, West Central Wireless (includes Five Star Wireless). T-Mobile is NOT liable for delayed or undelivered messages.
Takeda may be required to contact the user if an adverse event is reported
Takeda reserves the right to rescind, revoke, or amend the Program without notice at any time
You can unsubscribe from either the Reminder Program or Informational Program by texting STOP to 36395. For questions about the Programs, text HELP to 36395 or visit bit.ly/2C4d01L
For questions about TAKHZYRO, please contact your physician.

Yes, I agree to the terms and conditions of the TAKHZYRO Text Reminder Program. I hereby consent to receive text messages at the mobile number provided above. I understand this consent is not a condition of purchase or use of TAKHZYRO or any Takeda product or service. I understand that I may revoke this consent at any time.

Already taking TAKHZYRO? You can also sign up to receive text messages with dosing reminders.

PATIENT INFORMATION

TAKHZYRO^® (tak-ZYE-roe) (lanadelumab-flyo) injection, for subcutaneous use

Read this Patient Information before you start using TAKHZYRO and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of Hereditary Angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Before you use TAKHZYRO, tell your healthcare provider about all of your medical conditions, including if you:

are pregnant or planning to become pregnant. It is not known if TAKHZYRO can harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if TAKHZYRO passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby while using TAKHZYRO.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.

How should I use TAKHZYRO?

See the detailed Instructions for Use that comes with this patient information leaflet about the right way to prepare and inject TAKHZYRO.
Use TAKHZYRO exactly as your healthcare provider tells you to use it.
TAKHZYRO is given as an injection under your skin (subcutaneous) by you or a caregiver.
Your healthcare provider should show you or your caregiver how to prepare and inject your dose of TAKHZYRO before you inject yourself for the first time.
Do not try to inject TAKHZYRO unless you have been trained by your healthcare provider.
Self-injection is not recommended in children (2 to less than 12 years).

What are the possible side effects of TAKHZYRO?

TAKHZYRO may cause serious side effects, including allergic reactions. Allergic reactions may happen with TAKHZYRO. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

wheezing
difficulty breathing
chest tightness
fast heartbeat

faintness
rash
hives

The most common side effects of TAKHZYRO are:

injection site reactions (pain, redness, and bruising)
upper respiratory infections
headache

rash
dizziness
diarrhea
muscle aches

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of TAKHZYRO.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAKHZYRO for a condition for which it is not prescribed. Do not give TAKHZYRO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about TAKHZYRO that is written for health professionals.

What are the ingredients in TAKHZYRO?

Active ingredient: lanadelumab

Inactive ingredients: citric acid monohydrate, L-histidine, sodium chloride, sodium phosphate dibasic dihydrate and water for injection.

Please see full Prescribing Information and Important Safety Information. US-LANA-1881v1.0 05/23